News | April 23, 2024
AbbVie's phase 3 Select -GCA study of Upadacitinib showed positive results in patients with giant cell arteritis
Open a printable version of this pageEmail the URL of this page to a friend
Open a printable version of this pageEmail the URL of this page to a friend
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
The campaign marks an important milestone in its journey within the pharmaceutical manufacturing industry
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Submission based on results from pivotal phase III trial showing all primary endpoints met
Longest survival follow-up ever reported for immunotherapy treatment in this setting
CHL is strengthening its play in the fast-growing beauty and personal care sector
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The demand in Africa for COVID-19 vaccines has declined
Subscribe To Our Newsletter & Stay Updated
